Rosuvastatin is associated with increased risks for hematuria, proteinuria, and kidney failure with replacement therapy (KFRT) compared with atorvastatin use, according to a study published online July 19 in the Journal of the American Society of Nephrology. Jung-Im Shin, M.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues used deidentified electronic...
